Navigation Links
DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRi's Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Date:3/20/2008

ced multispectral in vivo imaging systems and our industry-leading data analysis tools," explains George Abe, CRi's President and CEO.

"We are pleased to partner with the Massachusetts General Hospital in this endeavor and are excited to enable our customers to further advance their small animal imaging capabilities", continued Abe.

CRi will be exhibiting the latest automated Maestro 2 system featuring DyCE along with CRi's cellular imaging solutions at the Annual Meeting of the American Association for Cancer Research (AACR), April 12 to 16 (Booth 235). Attendees can make an appointment to meet with a sales or technical representative by e-mailing aacr@cri-inc.com or calling (Toll-Free US) 1-800- 383-7924.

CRi is a Boston-based biomedical imaging company providing innovative optical imaging solutions to our customers for more than 20 years. Our multidisciplinary team is dedicated to working with our academic and commercial customers to provide high-value solutions. We provide comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. CRi's innovative solutions encompass sub-cellular, cellular and whole animal applications, and are being utilized around the world to enable breakthroughs in research, health and medicine.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177

(C) 1-781-405-4000

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
2. Allergic reactions to gadolinium-based contrast agents are rare, study finds
3. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
4. Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
5. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
6. New England Technology Foundation Announces Connecting for Childrens Charities 2008 Event
7. Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future
8. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
9. New Technology No Better at Spotting Anesthesia Awareness
10. Virtual reality and computer technology improve stroke rehabilitation
11. Advanced Technology in Dental Imaging Benefits Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 2Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 3Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 4Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 5Data Suggest that Pegasys May be an Option in Hepatitis C Patients,Unable to Tolerate Peg-Intron 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11